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Abstract: Concerns about the availability and 
use of methamphetamine in Europe have been 
growing for some time. Historically, the use of 
methamphetamine has been confined largely to 
the Czech Republic and Slovakia; however, 
recent signs of the spread of methamphetamine 
linked to different European countries have 
sparked further investigation of this topic. The 
methodology used is based on the triangulation 
of data collected using a number of investigative 
approaches and from multiple sources. The 
findings summarised in this paper include 
insights into the chemistry of methamphetamine 
and the history of its use in Europe since the 
1930s. Signs of increased involvement of 
organised crime groups in methamphetamine 
markets and possible scaling-up of production 
are noted. In some countries, there is evidence 
to suggest that methamphetamine use is 
increasing, while new injection trends have been 
detected among small groups of gay men in 
large cities (London, Paris). Worrying reports are 
emerging from south-east Europe that crystal 
methamphetamine smoking is a limited, but 
emerging, problem, with the possibility of 
spreading among vulnerable populations. 
Negative consequences for physical and mental 
health are associated with the use of 
methamphetamine, which may also involve high 
levels of sexual risk-taking. Evidence exists for 
effective health and social responses, based on 
cognitive behavioural and contingency 
management approaches. The study notes that 
the knowledge available in Europe on the use of 
methamphetamine and the associated problems 
remains incomplete, and highlights information 
and research gaps. The report concludes that, 
although methamphetamine use is not a major 
phenomenon in Europe, even at a relatively low 
prevalence, it is a drug that has the potential to 
cause significant harm. 
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insights from law enforcement, forensic science, pill 
testing, treatment, research and drug monitoring 
perspectives.
I Chemistry and pharmacology
Methamphetamine belongs to the phenethylamine chemical 
family, many members of which possess stimulant properties. 
Methamphetamine exists in two optical isomeric forms 
(enantiomers), d-methamphetamine and l-methamphetamine. 
Both the d- and l-enantiomers are psychoactive, having 
stimulant effects (Kuczenski et al., 1995; Mendelson et al., 
2006). The d-enantiomer is more potent, and its effects last 
longer than those of the l-enantiomer. At high doses, the 
l-enantiomer is reported to produce an intoxication similar to 
that caused by the d-enantiomer, but its psychoactive effects 
are relatively short-lived and less desired by experienced 
injecting methamphetamine users (Mendelson et al., 2006). 
Medicinal products containing methamphetamine may be 
used to treat attention-deficit hyperactivity disorder and 
exogenous obesity (Food and Drug Administration, 2013a). 
The l-enantiomer is used in non-prescription nasal 
decongestant products in the United States (Food and Drug 
Administration, 2013b). Illicit methamphetamine encountered 
in Europe is normally found to be a mixture of the d- and 
l-enantiomers in equal proportions, known in chemistry as a 
racemic mixture. Methamphetamine may exist in two forms: 
base and salt. The pure base is a clear, colourless, volatile oil, 
which is insoluble in water and can be readily converted into 
methamphetamine hydrochloride (the most prominent salt 
form). The hydrochloride salt form is a crystalline solid, which 
is soluble in water. In powder methamphetamine, granulated 
crystals are mixed with other ingredients such as lactose, 
dextrose or caffeine. Large white or translucent crystals of 
methamphetamine hydrochloride, suitable for smoking, can 
be produced from a starting material that has a high 
concentration of methamphetamine (base or hydrochloride). 
This is often called ‘ice’ or ‘crystal meth’, because of its 
appearance. Methamphetamine hydrochloride may also be 
found as an ingredient of tablets sold as ‘ecstasy’. 
Powder methamphetamine found on the illicit drugs market is 
similar to powder amphetamine in many ways, including purity 
and appearance, and the two are often indistinguishable, to 
both users and dealers. 
The method by which methamphetamine is administered 
depends on the form of the drug available. Powder 
methamphetamine tends to be administered in the same way 
as amphetamine powder, either inhaled intra-nasally (snorted) 
or dissolved and injected. Although smokable in this form, it is 
the larger crystals that are normally smoked, often in small 
I Background and methods
Concerns about the availability and use of 
methamphetamine (1) in Europe have been growing for some 
time. Historically, the use of methamphetamine has been 
confined largely to the Czech Republic and Slovakia, while 
elsewhere in Europe amphetamine has dominated the market 
for illicit amphetamines (2). The relatively high prevalence 
levels of crystal methamphetamine smoking reported in the 
United States and south-east Asia, however, have heightened 
concern and vigilance about the potential spread of this trend 
in European countries. During 2012 and 2013, reports of 
increasing methamphetamine use arising from different 
European countries have sparked interest in further 
investigation of this topic. These indications included the 
reported use of methamphetamine among heroin injectors in 
Greece, reports of increasing use of crystal 
methamphetamine in a number of Länder in Germany, 
evidence from drug seizures and forensic examinations of a 
market change from amphetamine to methamphetamine in 
some Nordic countries, and concerns about 
methamphetamine injection among groups of gay men in the 
United Kingdom.
In response to these disparate European developments, in 
July 2013, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) launched a trendspotter study on 
methamphetamine in Europe, which culminated in an expert 
meeting held in Lisbon on 19–20 September 2013. The study 
aimed to increase the overall understanding of 
methamphetamine trends in Europe, with a specific focus on 
production and trafficking issues, prevalence and patterns of 
use, health and social harms, and responses to the problem. 
The trendspotter methodology is based on the triangulation of 
data collected using a number of investigative approaches 
and from multiple sources. This methamphetamine study 
included the following:
n  a comprehensive, but non-systematic, review of the 
international literature on methamphetamine; 
n  a review of national reports from Reitox national focal 
points; 
n  an expert opinion survey conducted among four 
professional drug-related networks — the Reitox network 
of national focal points, Europol’s drugs network, a network 
of city-level drugs monitors and a panel of national experts; 
and
n  facilitated group discussions and presentations from 15 
national experts from 11 European countries (3), providing 
(1)  This report relates to N-methylamphetamine (N-methyl-1-phenylpropan-2-
amine), referred to as methamphetamine throughout the report.
(2)  ‘Amphetamines’ is the term used to describe amphetamine and 
methamphetamine together. 
(3)  Cyprus, Czech Republic, Germany, Greece, Italy, Latvia, Lithuania, 
Netherlands, Norway, Turkey, United Kingdom. 
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production has spread to new world regions, including South 
Africa, and more recently to Iran and west Africa, which may 
influence methamphetamine markets in Europe.
I History
From the 1930s onwards, Europe saw extensive prescribing of 
amphetamines for a range of medical reasons, including 
weight loss, treatment of fatigue, depression and narcolepsy, 
chronic alcoholism, cerebral arteriosclerosis and hay fever. It 
was the recognition of the stimulant properties of these 
medicines that made their non-medical use attractive, for 
example among students. One of the earliest sources of 
epidemiological data comes from Sweden, where a 1938 
survey reported that between 70 % and 80 % of students had 
ever used amphetamines pills. As mentioned above, 
stockpiles left over after the Second World War leaked onto 
the market in certain countries, and the 1960s saw another 
wave of amphetamines use in Europe. In the 1970s, countries 
began to outlaw unauthorised manufacture and sale of 
amphetamines, as amphetamine and methamphetamine 
became Schedule II drugs under the 1971 United Nations 
Convention on Psychotropic Substances. From the 1970s on, 
methamphetamine was eclipsed by amphetamine in most 
European countries, although increasingly it was 
overshadowed by heroin, which tended to dominate high-risk 
forms of use from the 1980s onwards. 
In the 1970s and later, methamphetamine use was largely 
restricted to what is now the Czech Republic, though it 
appeared sporadically in the Swedish amphetamines market, 
and in recreational settings in some countries (e.g. the 
German dance scene). From around 2000, methamphetamine 
spread into the drug scenes in the Czech Republic and 
Slovakia, where it is now used by a high proportion of these 
countries’ high-risk drug users.
I Production and precursors
The scale of methamphetamine production in Europe appears 
to be limited when compared with the overall global figures 
(EMCDDA and Europol, 2013). In 2011, the United Nations 
Office on Drugs and Crime received 350 reports of dismantled 
methamphetamine production sites from European countries, 
most of these (328) reported by the Czech Republic. Europol 
has identified two main producer regions: one in central 
Europe, focused around the Czech Republic and neighbouring 
countries, Slovakia and Germany, and the other in the Baltic 
States, centred on Lithuania. Production in the Czech 
Republic is mainly in small-scale so-called kitchen 
laboratories, with the output destined primarily for distribution 
glass pipes, but these may also be dissolved and injected or 
crushed and snorted.
The purity of methamphetamine depends to a large extent on 
the addition of cutting agents. Powder methamphetamine is 
more likely to contain adulterants and tends to be of lower 
purity than the crystal form of the drug. Adulteration of crystal 
methamphetamine, though rare, has been documented 
outside Europe.
I International context
Methamphetamine was first synthesised in 1893 in Japan as 
a powder and later in the crystalline form (1918/19). Since 
then, the drug has been used in a variety of contexts. In the 
1930s and 1940s, amphetamines-based medicines were 
widely prescribed and used. During the Second World War, 
troops from Japan, the United States, the United Kingdom and 
Germany, among other countries, were given amphetamines 
to stay awake for long periods of time. The spread of non-
medical use of methamphetamine in the general public of 
these countries in the years that followed has been largely 
attributed to stocks of pills left over from the war. Between 
1945 and 1955, the first methamphetamine epidemics were 
documented in the United States (Shrem and Halkitis, 2008) 
and Japan (National Institute of Mental Health, cited in 
Ahmad, 2003). Both countries experienced second epidemic 
waves — the United States during the 1960s and 1970s, and 
Japan during the late 1980s and early 1990s, the latter 
coinciding with a sharp increase in methamphetamine use in 
China, evidenced by increases in methamphetamine-related 
fatalities across the country.
In the mid-1990s, a third methamphetamine epidemic 
occurred in the United States and Japan, and, during this 
period, other countries in south-east and east Asia and 
Oceania, particularly Australia and Thailand, showed signs of 
peaking methamphetamine epidemics (McKetin et al., 2008). 
Since 2000, both South Africa (Pluddemann et al., 2013) and 
North Korea have experienced a rapid upsurge in 
methamphetamine use (Lankov and Kim, 2013). More 
recently, Iran has started to document increasing 
methamphetamine use among injecting drug users (Mehrjerdi 
and Noroozi, 2013). 
In the global context, methamphetamine continues to be the 
most seized of the amphetamines, with reported worldwide 
seizures of 88 tonnes in 2011, an increase of 73 % compared 
with the previous year (UNODC, 2013). World 
methamphetamine production remains concentrated in North 
America (Mexico, United States) and the Asia-Pacific region 
(China, Indonesia, Malaysia, Thailand), close to the major 
consumer markets. Since the mid-2000s, however, large-scale 
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There is a need for continued vigilance with regard to changes 
in production, particularly the possibility of a switch to 
methamphetamine production in countries such as Bulgaria 
or Poland, where, historically, amphetamine has been 
produced. There are a number of reasons why this might 
occur. As methamphetamine production requires only basic 
equipment and rudimentary knowledge, the laboratories can 
be set up and taken down quickly in order to avoid detection, 
and a range of precursors and pre-precursors can be used 
(including readily available over-the-counter medicinal 
products).
I Trafficking and availability
Insights into patterns and trends in illicit drug markets are 
provided by seizures data. Between 2006 and 2011, the 
number of methamphetamine seizures reported to the 
EMCDDA nearly tripled, while the quantities of seized 
methamphetamine increased sixfold. In 2011, almost 9 500 
seizures, adding up to one tonne of the drug, were reported to 
the EMCDDA by 22 countries. The largest quantities of 
methamphetamine were seized in Turkey, followed by Norway, 
Lithuania, Sweden and Latvia. In recent years, the highest 
number of seizures has been reported by Sweden and 
Norway. Turkey first reported seizing methamphetamine in 
2009, following the emergence of Iran as a producer country 
and the use of Turkey as a transit country for export of the 
drug to the Asia-Pacific region. 
Methamphetamine produced in Lithuania is reportedly 
trafficked to Norway and Sweden, where it appears to have 
displaced amphetamine (EMCDDA, 2013a). Another intra-
European trafficking route is located in Central Europe, where 
Vietnamese organised crime groups are reported to be 
increasingly involved in both the production and trafficking of 
methamphetamine. In a relatively new development, 
methamphetamine is being produced in the Czech Republic, 
and then exported to German markets in Bavaria and Saxony, 
as well as Austria and Scandinavian countries. 
Methamphetamine seizures in both the Czech Republic and 
Germany have been on the rise in recent years. Germany has 
seen an almost 10-fold increase between 2008 and 2012 in 
reported cases, and an almost 20-fold increase in quantities 
seized (in 2012, Germany reported 3 512 seizures amounting 
to 75.2 kg of methamphetamine). The increased number of 
seizures of methamphetamine in Germany have not been 
matched by signs of increased production of the drug in the 
country. The methamphetamine laboratories uncovered in 
Germany continue to be small-scale and remain in the range 
of 10–15 a year. Despite growing demand for 
methamphetamine in Germany, there are no signs of 
increased domestic production, with a stable low number of 
small-scale laboratories (between 10 and 15) dismantled 
within the country. Here, methamphetamine powder is known 
as ‘pervitin’, the name of an obsolete pharmaceutical product 
containing methamphetamine, which was made in the region. 
In the last two years, however, there have been more 
laboratories recorded with higher production capacity, and 
new players (Vietnamese organised crime groups) have 
become increasingly involved in the production of 
methamphetamine for export. Production in Lithuania tends 
to take place in medium-sized laboratories, which produce the 
drug ‘on demand’, for export to Nordic countries and the 
United Kingdom (EMCDDA and Europol, 2009). Six 
methamphetamine laboratories have been dismantled in 
Lithuania since 1997. Recent data on dismantled production 
sites indicate that methamphetamine has also been produced 
on a small scale in other parts of Europe, including Belgium, 
Bulgaria, Greece, Hungary, the Netherlands, Poland, Serbia 
and the United Kingdom. 
In Europe, methamphetamine is produced using five main 
methods. Three of them (lithium/ammonia, hydrophosphorous 
acid/iodine, hydriodic acid/red phosphorus) are simple 
one-step chemical reactions using ephedrine or 
pseudoephedrine as the starting material. In the remaining 
two methods (the Leuckart method and the reductive 
amination method), 1-phenyl-2-propanone (benzyl methyl 
ketone, BMK) is used as a precursor. Methods based on 
ephedrine and pseudoephedrine are mainly used in Central 
Europe (Czech Republic, Germany, Poland, Slovakia), whereas 
production of methamphetamine from BMK is characteristic 
for Lithuania. Laboratories using both approaches have been 
identified in the Netherlands. Historically, methamphetamine 
precursors such as BMK were produced outside Europe, for 
example in China and Russia. In recent years, however, BMK 
has been increasingly produced within Europe, from pre-
precursors including APAAN (alpha-phenylacetoacetonitrile), a 
substance not covered by international precursor controls (4). 
In addition, pseudoephedrine is extracted from over-the-
counter pharmaceutical products available in a number of 
countries. Following the introduction of restrictions on the sale 
of medicines containing pseudoephedrine in the Czech 
Republic in 2009, an increase in imports of these medicines 
from neighbouring countries has been reported, mainly from 
Poland. A new production method has been reported from 
Serbia, where ephedrine and pseudoephedrine are produced 
from L-PAC (phenylacetyl carbinol). Use of this new pre-
precursor may influence production methods in other 
countries, where ephedrine and pseudoephedrine are 
currently used as starting materials.
(4)  Since 2010, facilities converting APAAN to BMK have been dismantled in 
Belgium, Germany, the Netherlands and Poland. In all cases, the pre-
precursor was shipped from China. As BMK is a precursor for both 
methamphetamine and amphetamine, the final substance to be produced is 
not known (EMCDDA, 2013b). 
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countries), and that primary opioid users are using 
methamphetamine as a secondary substance (e.g. Greece). A 
picture emerges of a number of distinct regional trends in 
methamphetamine use within Europe, each with its own 
characteristics and patterns of use, and these are summarised 
below.
For the Czech Republic and Slovakia, the use of domestically 
produced methamphetamine, locally known as pervitin, is well 
documented, and trends in use in the general population 
appear to be stable or declining. The most recent results from 
surveys on drug use show last-year prevalence for young 
people (aged 15–34) to be 1 % in the Czech Republic in 2011, 
with lifetime prevalence for the same group at 3 % in Slovakia 
in 2010. Lifetime prevalence for school students aged 15–16 
years was reported at 2 % in the Czech Republic in 2011, 
down from a peak of 5.5 % in 1999, and at 3 % in Slovakia in 
2010, down from just under 5 % in 2006. In these countries, 
methamphetamine is the drug most often reported by those 
seeking treatment for problems related to drug use, and it is 
worrying that both countries have reported an increase in the 
numbers entering treatment for methamphetamine-related 
problems in recent years. Only the Czech Republic has 
sufficient data to chart the longer-term trend in the numbers 
using methamphetamine in a high-risk fashion, which 
increased from 21 800 in 2002 to 30 700 in 2012.
Reports of increased use of crystal methamphetamine in 
Germany appear to be directly linked with the involvement of 
organised crime groups in the Czech Republic and sale in the 
border areas. Although large crystals have been seized in 
Germany, this form of the drug is used in similar ways to 
powder methamphetamine, and smoking is not a documented 
problem. The main users of the drug are young adults, who 
primarily sniff the drug. However, recent increases have been 
reported in the numbers entering treatment for 
methamphetamine problems and in deaths related to the drug 
in some German Länder.
In the north of Europe, methamphetamine use is highly 
interlinked with the older, more established amphetamine 
market, with signs of a shift towards increased supply and use 
of methamphetamine. As methamphetamine has accounted 
for more than half of the number of seizures of amphetamines 
in Norway in recent years, it is likely that a high proportion of 
the country’s amphetamines users are using 
methamphetamine. The two drugs may be sold 
interchangeably, and it is difficult for users to distinguish the 
effects (Norwegian national focal point, 2012). A long-running 
Latvian cohort study of problem drug users has also observed 
an upward trend in the use of this drug (Centre of Health 
Economics, 2011), with an increase in reports of primary 
amphetamines users (mainly methamphetamine) from 42 % in 
2007 to 53 % in 2010. The most recent data, however, indicate 
that the rise of methamphetamine has stalled, at least in 
each year. A sizeable increase in the amount of 
methamphetamine seized was also reported by Greece: from 
around 1 kg in 2012 to over 14 kg in the first seven months of 
2013. There continues to be great variation in national reports 
on methamphetamine price and purity. 
I Europe as a transit territory
Since the late 2000s, Europe has been used as a transit zone 
for methamphetamine produced outside Europe and destined 
for Asia-Pacific countries such as Australia, Indonesia, Japan, 
Malaysia and Thailand. In 2011, a joint operation between 
Bulgarian, Romanian and Turkish authorities resulted in the 
seizure of 55 kg of methamphetamine due to be smuggled to 
Japan. This new trend in trafficking appears to be linked to the 
recent emergence of new production sites located in West 
Africa (Gambia, Nigeria) and Iran, and some European 
countries (Belgium, France, United Kingdom) have reported 
increases in the numbers of seizures of the drug en route from 
Africa to Asia-Pacific countries. There is no information to 
suggest that methamphetamine produced in West Africa is 
destined for the European market. There is, however, evidence 
to suggest that some of the methamphetamine produced in 
Iran and trafficked through Turkey along well-established 
heroin routes is destined for the European market. In 2011 and 
2012, Turkish law enforcement authorities identified attempts 
to deliver relatively small amounts of methamphetamine from 
Iran to Belgium and the United Kingdom. Other countries 
affected by the organised trafficking of methamphetamine 
from Turkey via land routes include Bulgaria, Greece and 
Romania. In addition, there have been some indications of 
possible small-scale methamphetamine production in Turkey 
(Ekici and Ozbay, 2013).
I Regional patterns
In the context of the market for illicit stimulants in Europe, 
methamphetamine is a minor player. Of the estimated 
1.7 million (1.3 %) young Europeans (aged 15–34) who have 
used amphetamines in the last year, the majority will have 
used amphetamine. Evidence from a pan-European multi-city 
wastewater analysis confirms the existence of regional 
patterns in the use of amphetamines, identifying higher 
concentrations of amphetamine in wastewater from cities in 
the Netherlands and Belgium, whereas methamphetamine 
levels were highest in Czech and Norwegian cities. Apart from 
the Czech Republic and Slovakia, very few countries have 
identified significant numbers of problem methamphetamine 
users. However, it is possible that, in some countries, problem 
amphetamine users are also interchangeably and sometimes 
unknowingly using methamphetamine (northern European 
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psychopathological harms associated with the use of 
amphetamines include psychosis, depression, suicidal 
behaviour, anxiety and violent behaviour (Darke et al., 2008). 
High levels of co-morbidity is a recognised problem among 
users seeking treatment. 
The evidence from this data collection illustrates that a 
number of these problems have been identified in European 
studies of drug users. Expert reports of methamphetamine 
users in Athens, for example, emphasise problems associated 
with violence, psychosis, poor physical health and emaciation. 
In addition, in the Czech Republic, although the overall 
number of overdose deaths linked with methamphetamine is 
reported to be low, there are relatively high levels of accidents 
and suicides reported for high-risk users of this drug 
compared with the general population.
High levels of sexual risk-taking among users of 
amphetamines (both injectors and non-injectors) may 
contribute to an increased risk of contracting human 
immunodeficiency virus (HIV) and other sexually transmitted 
infections (Degenhardt et al., 2008). This is a public health 
concern for gay men participating in slamming parties, with 
experts reporting poor adherence to HIV medication and 
increased rates of hepatitis C virus reinfection among this 
group. Although the injection of drugs is generally on the 
decline across Europe, it is particularly worrying that this new 
phenomenon known as slamming is going against the trend.
I Health and social responses 
Outside the Czech Republic and Slovakia, much of Europe’s 
drug treatment provision has been developed in response to 
heroin use and related problems. As with research on harms, 
studies examining the health and social responses to 
problems linked with methamphetamine use come primarily 
from Australia and the United States. The available evidence 
supports the efficacy of two psychosocial or behavioural 
treatment approaches for methamphetamine dependence: 
cognitive behavioural approaches and contingency 
management. Cognitive behavioural approaches, in 
conjunction with pharmacotherapy or as a standalone 
intervention, have been shown to increase treatment 
attendance and to reduce methamphetamine use and risky 
sexual behaviour (Lee and Rawson, 2008; McElhiney et al., 
2009; Reback and Shoptaw, 2011). Similarly, contingency 
management has been associated with better retention in 
treatment, lower rates of methamphetamine use and longer 
periods of sustained abstinence over the course of their 
treatment experience (Roll et al., 2013). 
Although a number of efficacy trials of potential 
methamphetamine pharmacotherapies (e.g. bupropion, 
Norway. In addition, the number entering treatment in Norway 
for problems related to amphetamines has declined from 
1 110 in 2010 to 710 in 2012. 
In a number of countries in southern Europe, evidence of a 
fledgling trend in crystal methamphetamine smoking has 
been observed. Use of methamphetamine in crystal form, 
locally known as ‘sisa’ or ‘shisha’, has been reported from 
Greece since 2010, both by low-threshold and treatment 
services. The drug appears to be primarily smoked in glass 
pipes, though it can also be injected. According to the reports 
from methamphetamine users in Athens, the drug is mainly 
used by young drug users, groups of immigrants and heroin 
users. There are particular concerns that the economic crisis 
might affect and facilitate the spread of crystal 
methamphetamine smoking among vulnerable populations. 
Recently, new reports of crystal methamphetamine smoking 
(and related deaths) have also been received from Turkey and 
Cyprus. 
There is some documentation on the use of 
methamphetamine by specific groups within the population, 
such as clubbers and gay men in Europe. Of recent concern 
are reports of the use of methamphetamine, including 
injection of the drug, among some groups of gay men, mainly 
in London — although also reported in Paris — in the context 
of so-called ‘slamming’ or ‘chem-sex’ parties. These parties 
can last several days and involve multiple sexual partners and 
the use of a cocktail of drugs, with injecting equipment often 
being shared and condoms not used (Kirby and Thornber-
Dunwell, 2013). In this milieu, methamphetamine is generally 
used alongside mephedrone, gamma-hydroxybutyrate (GHB) 
and sildenafil. Although the extent of this type of drug use 
remains unclear, specialist lesbian, gay, bisexual and 
transgender drug services in London have reported increasing 
demand for treatment linked to problems associated with 
methamphetamine use by gay men.
I Methamphetamine-related harms 
Most research on the health consequences of amphetamines 
use has been conducted in Australia and the United States, 
where crystal methamphetamine smoking is a major problem. 
Although the findings of these research efforts may 
sometimes be more specific to drug use patterns that are 
uncommon in Europe, in many instances they are applicable 
to users of powder amphetamines, including injectors. 
Illicit use of amphetamines is associated with a range of 
negative consequences (Darke et al., 2008), including 
psychosis, cardiovascular and cerebrovascular problems, 
dependence, psychological and psychiatric problems, 
infectious diseases and death. The most serious 
EMCDDA PAPERS I Exploring methamphetamine trends in Europe
7 / 10
morbidity, an area that would greatly benefit from targeted 
cohort studies. 
Gaps also exist in the information available on the market for 
methamphetamine in Europe, especially on the production 
and supply of the drug. Among the information needs that can 
be identified is one for strengthened forensic data. For 
example, improved chemical profiling, which provides 
information on the enantiomers present, can help to identify 
the method that was used to produce the drug. Also needed in 
Europe is more data on production laboratories, including the 
types of facility, their size and their capacity, in addition to 
improved data on the price and purity of methamphetamine. 
Finally, the value of intelligence-gathering on organised crime 
groups is recognised, in particular the insight that this may 
provide on the dynamics, supply chains and key players 
involved in the various methamphetamine markets.
I Conclusion
Although methamphetamine use is not a major phenomenon 
in Europe, it is evident from this investigation that, even at a 
relatively low prevalence, it is a drug that has the potential to 
cause significant harm. Both the Czech Republic and Slovakia 
report longer-term entrenched patterns of methamphetamine 
use and recent increases in treatment demand that are as yet 
unexplained. Evidence from northern Europe shows a more 
static situation, with methamphetamine interlinked with 
amphetamine, and feeding an existing market. In addition, 
there are signs of increased involvement of organised crime 
groups in methamphetamine markets and possible scaling-up 
of production. In some countries, such as Germany and Latvia, 
methamphetamine use is reportedly increasing. New injection 
trends have been detected among small groups of gay men in 
large cities (London, Paris), a phenomenon that requires close 
monitoring. Finally, there are particularly worrying signs from 
Greece, and to a lesser extent Cyprus and Turkey, where, for 
the first time in Europe, crystal methamphetamine smoking is 
identified as an emerging threat, with the possibility of 
spreading among vulnerable populations. 
modafinil) have been carried out, all candidate drugs have 
been no more effective than a placebo. Consequently, there 
are no approved medications for treating methamphetamine 
dependence, and pharmacotherapy is recommended as an 
adjunct to psychosocial interventions rather than being a 
primary component of treatment (Brackins et al., 2011; Karila 
et al., 2010).
Distributing gelatine capsules to injecting methamphetamine 
users, for oral administration of the drug in order to reduce 
injecting-related harm, has been tested in the Czech Republic 
(Mravcik et al., 2011). Other interventions that have been 
implemented in order to reduce the risks associated with 
injection include the provision of smoking equipment or 
safer-smoking kits through needle and syringe programmes. 
Health promotion initiatives targeted towards 
methamphetamine users tend to focus on general safety 
issues and self-care, including mental health, physical and 
sexual health. 
I Information and monitoring gaps
The knowledge available in Europe on the use of 
methamphetamine and the associated problems remains 
incomplete, and a number of information and research gaps 
can be identified. Reports of drug seizures continue to offer 
the only standardised, comparable dataset on 
methamphetamine at EU level. Other epidemiological 
measures are not collected systematically or are often 
aggregated, with methamphetamine and amphetamine being 
placed together as ‘amphetamines’ in population surveys and 
data on treatment entrants. It is hoped that a new protocol for 
collecting information on treatment entrants, which is to be 
introduced in 2014, will help to address this problem. The 
collection of data on the prevalence of drug use in the general 
population remains in the hands of national decision-makers, 
and very few countries choose to collect prevalence data on 
methamphetamine use. There is also the additional challenge 
that, in some countries, users of the drug will not be aware 
whether they are using amphetamine or methamphetamine. 
Concerns have also been raised with regard to major gaps in 
our knowledge regarding methamphetamine-related 
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